Catalyst Wire Dossier Catalyst Wire Dossier

Uproleselan (GMI-1271)

uproleselan · GlycoMimetics Incorporated
Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for Uproleselan (GMI-1271), covering 2023-07-10 to 2024-07-29. Get the full timeline:

Most recent: Clinical Trial Update: Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia [Phase 3]

See pricing